The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase ...

In recent years, inhibiting PCSK9, a serine proteinase that regulates cholesterol metabolism, has been demonstrated to be a method enhancing the antitumor effects of anti-PD-1/PD-L1 treatment to ...

Monoclonal antibodies (mAbs) are medications that target specific proteins to help reduce inflammation in people with severe asthma. The FDA has approved six mAbs for asthma treatment so far.

15. Previous (within 90 days before randomization), current or planned treatment with a PCSK9 monoclonal antibody (mAb). 16. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy ...

5. Previous treatment with a mAb directed towards PCSK9 (e.g., evolocumab, alirocumab) or planned use after screening visit. 6. Previous treatment prior to screening with BPA within 90 days 7.

Antonio Abreu (Portugal) was appointed Director of the Division of Ecological and Earth Sciences in the Natural Sciences Sector of UNESCO and Secretary of the MAB Programme in April 2023.